Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

3 One-Drug Biotech Wonders



For Seattle Genetics, Medivation, and Regeneron, one drug is enough.

For Seattle Genetics, Medivation, and Regeneron, one drug is enough.



Total Views
Views on SlideShare
Embed Views



9 Embeds 1,880

http://www.fool.com 1680
http://www.scoop.it 108
http://www.dailyfinance.com 81
http://www.barchart.com 4
http://translate.googleusercontent.com 3
http://cms.fool.com 1
http://mockup.www.fool.com 1
http://m.fool.com 1
http://cached.newslookup.com 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

3 One-Drug Biotech Wonders 3 One-Drug Biotech Wonders Presentation Transcript

  • 3 One-Drug Biotech Wonders
  • Sometimes One Is Enough • Biotechs often lose money for the first decade or more of their existence. • Going from no revenue to any revenue can drive stock price higher.
  • Seattle Genetics • Adcetris approved by FDA in 2011 to treat Hodgkin lymphoma and anaplastic large cell lymphoma after prior treatment failure. • Sold outside U.S. and Canada by partner Takeda Pharmaceutical • Receives revenue from partners that use Seattle Genetics’ technology to develop their drugs. Source: Seattle Genetics
  • Seattle Genetics
  • • Xtandi approved by FDA in 2012 to treat prostate cancer that has spread and has not responded to chemotherapy • Sold in U.S. with Astellas Pharma • Outside U.S., Astellas pays royalty from the low teens to the low twenties on aggregate net sales of Xtandi Source: Medivation
  • • Not technically a one-drug company, but other drugs added just $4 million in the third quarter. • Eylea, which treats macular degeneration, contributed $363 million. • Sold by Bayer HealthCare outside the U.S. where Regeneron gets half the profits. Source: Regeneron Pharmaceuticals
  • Check Out These Returns Company Date of approval Return since approval Seattle Genetics August 19, 2011 201% Medivation August 31, 2012 61% Regeneron November 18, 2011 465% Returns through January 29, 2014.
  • Biotechs Hoping to Be 1-Drug Wonders • Chelsea Therapeutics (NASDAQ: CHTP) – Developing Northera for neurogenic orthostatic hypotension (dangerously low blood pressure) – FDA decision expected by February 14, 2014 • MannKind (NASDAQ: MNKD) – Developing inhaled insulin Afrezza for diabetics – FDA decision expected by April 15, 2014 • Durata Therapeutics (NASDAQ:DRTX) – Developing Dalvance for bacterial skin infections – FDA decision expected by May 26, 2014
  • The Motley Fool’s Top Stock For 2014